Newtyn Management Amends Sensei Biotherapeutics Stake
Ticker: SNSE · Form: SC 13D/A · Filed: Mar 7, 2024 · CIK: 1829802
| Field | Detail |
|---|---|
| Company | Sensei Biotherapeutics, Inc. (SNSE) |
| Form Type | SC 13D/A |
| Filed Date | Mar 7, 2024 |
| Risk Level | medium |
| Pages | 11 |
| Reading Time | 13 min |
| Key Dollar Amounts | $0.0001, $807,535, $1,031,194, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: ownership-change, sec-filing, schedule-13d
Related Tickers: SNSE
TL;DR
Newtyn Management just updated its stake in Sensei Bio. Watch this space.
AI Summary
Newtyn Management, LLC, a significant shareholder, filed an amendment (Amendment No. 2) to its Schedule 13D on March 7, 2024, regarding its holdings in Sensei Biotherapeutics, Inc. The filing indicates a change in the beneficial ownership of the company's common stock, though specific details of the change and the new ownership percentage are not provided in this excerpt.
Why It Matters
This filing signals a potential shift in the ownership structure of Sensei Biotherapeutics, which could impact the company's strategic direction and stock performance.
Risk Assessment
Risk Level: medium — Schedule 13D filings often precede significant corporate actions or shifts in control, introducing uncertainty for investors.
Key Players & Entities
- Newtyn Management, LLC (company) — Filing entity
- Sensei Biotherapeutics, Inc. (company) — Subject company
- March 7, 2024 (date) — Filing date
- March 5, 2024 (date) — Date of event requiring filing
FAQ
What specific changes in beneficial ownership are detailed in this Amendment No. 2 to the Schedule 13D?
This excerpt does not provide the specific details of the changes in beneficial ownership, only that an amendment has been filed.
What is the primary purpose of a Schedule 13D filing?
A Schedule 13D filing is required for any person or group who acquires beneficial ownership of more than five percent of a class of registered equity securities, and it discloses information about the filer's background, purpose, and plans.
Who is the subject company of this filing?
The subject company is Sensei Biotherapeutics, Inc.
Who is the entity filing the Schedule 13D/A?
The entity filing is Newtyn Management, LLC.
When was this amendment filed with the SEC?
This amendment was filed on March 7, 2024.
Filing Stats: 3,233 words · 13 min read · ~11 pages · Grade level 11.3 · Accepted 2024-03-07 18:00:48
Key Financial Figures
- $0.0001 — Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class o
- $807,535 — neficially owned by NP is approximately $807,535, including brokerage commissions. The a
- $1,031,194 — eficially owned by NTE is approximately $1,031,194, including brokerage commissions. Ite
- $1.00 — outstanding Shares at a price equal to $1.00 per share in cash, representing a premi
Filing Documents
- formsc13da.htm (SC 13D/A) — 287KB
- 0001493152-24-009294.txt ( ) — 288KB
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of his knowledge and belief, each of the undersigned certifies that the information set forth in this Dated: March 7, 2024 Newtyn Partners, LP By: Newtyn Management, LLC Investment Manager By: /s/ Eugene Dozortsev Name: Eugene Dozortsev Title: Authorized Signatory Newtyn TE Partners, LP By: Newtyn Management, LLC Investment Manager By: /s/ Eugene Dozortsev Name: Eugene Dozortsev Title: Authorized Signatory Newtyn Management, LLC By: /s/ Eugene Dozortsev Name: Eugene Dozortsev Title: Authorized Signatory Newtyn Capital Partners, LP By: Ledo Capital, LLC General Partner By: /s/ Eugene Dozortsev Name: Eugene Dozortsev Title: Authorized Signatory Ledo Capital, LLC By: /s/ Eugene Dozortsev Name: Eugene Dozortsev Title: Authorized Signatory 12 CUSIP No. 81728A108 /s/ Noah Levy Noah Levy 13 CUSIP No. 81728A108 SCHEDULE A The following table details the transactions by the Reporting Persons in Shares of Common Stock during the period commencing sixty (60) days prior to March 6, 2024. Nature of the Transaction Securities Purchased/(Sold) Price Per Share($) Date of Purchase / Sale NEWTYN PARTNERS, LP Sale of Common Stock (574 ) 0.8170 2/2/2024 Sale of Common Stock (2,728 ) 0.8149 2/5/2024 Sale of Common Stock (18,136 ) 0.8342 2/6/2024 Sale of Common Stock (31,389 ) 0.8244 2/9/2024 Sale of Common Stock (500 ) 0.8425 2/12/2024 Sale of Common Stock (9,193 ) 0.7942 2/13/2024 Sale of Common Stock (10,010 ) 0.7725 2/16/2024 Sale of Common Stock (13,250 ) 0.7735 2/21/2024 Sale of Common Stock (1,338 ) 0.7641 2/23/2024 Sale of Common Stock (10,000 ) 0.7850 2/26/2024 Sale of Common Stock (22,892 ) 0.7824 2/27/2024 Sale of Common Stock (31,373 ) 0.8398 2/28/2024 Sale of Common Stock (31,508 ) 0.8496 2/29/2024 Sale of Common Stock (9,0